Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...
Shares of Bristol Myers Squibb (BMY) are surging after the FDA approved the pharmaceutical giant's schizophrenia drug, making ...